Merganser Biotech snags $28 mln Series A
Merganser Biotech Inc, which focuses on treating rare blood and iron-related diseases, has secured $28 million in Series A financing. Novartis Venture Fund led the round with participation from Frazier Healthcare, Sutter Hill Ventures, Osage University Partners, BioAdvance and Stateside Developments. In addition to the funding, Markus Goebel of Novartis Venture Fund, James Topper of Frazier Healthcare and Jeffrey Bird of Sutter Hill Ventures have been added to Merganser's board of directors. Also, Bill Harrington of Osage University Partners has been named as a board observer.
19 February 2015•3 mins read
